CYP2C19 CRISPR Activation Plasmid (h): sc-404808-ACT

Human CYP2C19 encodes a cytochrome P450 monooxygenase that catalyzes oxidative biotransformation of diverse xenobiotics and endogenous substrates in the endoplasmic reticulum. As part of phase I metabolism, CYP2C19 supports redox cycling through NADPH–cytochrome P450 reductase and shapes metabolic flux that can influence downstream conjugation and clearance pathways. Variation in CYP2C19 expression and activity is linked to interindividual differences in drug metabolism, chemical sensitivity, and susceptibility to adverse responses in pharmacogenomics-associated conditions. CYP2C19 regulation is also studied in the context of hepatic differentiation, nuclear receptor signaling networks, and inflammation-driven transcriptional reprogramming that alters metabolic capacity.

CYP2C19 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous CYP2C19 expression without altering the underlying DNA sequence.

CYP2C19 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the CYP2C19 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.

Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the CYP2C19 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous CYP2C19 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native CYP2C19 locus and enabling the study of CYP2C19-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of CYP2C19 pathway restoration in tumor cells with silenced or reduced CYP2C19 expression.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.